Perspective Therapeutics, Inc. (CATX)
Quote, stock score, analyst consensus, and SEC filings, plus insider and Congress trades when there are any.
NYSE American · Price as of · Nasdaq Real Time Price
- Analysts14
- Implied upside+864.4%
- Target range$4.00 to $18.00
- EPS expected-$0.25
- A year ago-$0.35
- Revenue expected$47,810 -77%
- Estimate range-$0.31 to -$0.22
SEC filings
| Form | Filed | Description |
|---|---|---|
| 8-K | October 23, 2026 | 8-K |
| 8-K | October 8, 2026 | 8-K |
| 8-K | October 1, 2026 | 8-K |
| SCHEDULE 13D/A | September 23, 2026 | View on EDGAR |
| 8-K | September 14, 2026 | 8-K |
| 8-K | September 8, 2026 | 8-K |
| 4 | September 8, 2026 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES |
| 4 | September 4, 2026 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES |
Articles that mention Perspective Therapeutics without it being the main subject.
Frequently asked questions
When does CATX report earnings?
Perspective Therapeutics, Inc. (CATX) is scheduled to report quarterly results on November 9, 2026 (estimated). The 11-analyst consensus is -$0.25 per share on revenue of $47,810 for the quarter ended September 30, 2026, against -$0.35 and $209,000 a year earlier. It has beaten the consensus EPS estimate in 2 of the last four quarters. The date is an estimate from past reporting patterns and can move until the company confirms it.
What do analysts expect for CATX?
14 analysts cover Perspective Therapeutics, Inc. (CATX). The consensus rating is Strong buy. The average price target is $11.43, in a range of $4.00 to $18.00.
Are insiders buying or selling CATX?
We have no qualifying Form 4 insider purchases or sales on record for Perspective Therapeutics, Inc. (CATX). Sales are only tracked above a dollar threshold, so small routine trades may not appear.
Where can I see CATX SEC filings?
Recent filings are listed on this page, newest first. The latest is an 8-K filed October 23, 2026.